CanSino Biologics 과거 수익 실적
과거 기준 확인 0/6
CanSino Biologics's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 7.8% per year.
주요 정보
-33.9%
수익 성장률
-32.9%
EPS 성장률
Biotechs 산업 성장 | 11.0% |
매출 성장률 | 7.8% |
자기자본 수익률 | -14.6% |
순이익 | -96.2% |
최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?
Jun 20The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%
Jan 11수익 및 비용 분석
CanSino Biologics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 24 | 749 | -720 | 572 | 449 |
30 Jun 24 | 635 | -867 | 573 | 486 |
31 Mar 24 | 371 | -1,513 | 619 | 585 |
31 Dec 23 | 357 | -1,483 | 655 | 638 |
30 Sep 23 | 503 | -1,420 | 573 | 691 |
30 Jun 23 | 431 | -1,763 | 599 | 793 |
31 Mar 23 | 636 | -1,170 | 569 | 771 |
31 Dec 22 | 1,035 | -909 | 544 | 778 |
30 Sep 22 | 1,921 | 106 | 487 | 772 |
30 Jun 22 | 2,868 | 989 | 434 | 651 |
31 Mar 22 | 4,332 | 2,050 | 408 | 766 |
31 Dec 21 | 4,300 | 1,914 | 329 | 879 |
30 Sep 21 | 3,105 | 1,113 | 246 | 908 |
30 Jun 21 | 2,082 | 643 | 187 | 872 |
31 Mar 21 | 488 | -388 | 103 | 659 |
31 Dec 20 | 25 | -397 | 95 | 428 |
30 Sep 20 | 6 | -239 | 75 | 234 |
30 Jun 20 | 4 | -189 | 64 | 202 |
31 Mar 20 | 6 | -135 | 79 | 191 |
31 Dec 19 | 2 | -157 | 65 | 152 |
30 Sep 19 | 6 | -137 | 66 | 127 |
30 Jun 19 | 11 | -156 | 69 | 122 |
31 Mar 19 | 9 | -158 | 40 | 89 |
31 Dec 18 | 9 | -138 | 46 | 114 |
31 Dec 17 | 9 | -64 | 16 | 68 |
31 Dec 16 | 8 | -50 | 10 | 52 |
양질의 수익: 6185 is currently unprofitable.
이익 마진 증가: 6185 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: 6185 is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
성장 가속화: Unable to compare 6185's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: 6185 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
자기자본 수익률
높은 ROE: 6185 has a negative Return on Equity (-14.61%), as it is currently unprofitable.